Sign in or create an account to add this stock to your watchlist.
About Flexion Therapeutics (NASDAQ:FLXN)
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee. The company also develops FX101 and FX201, which is a pre-clinical stage programs for the treatment OA of large joints. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FLXN
CUSIPN/A
Phone781-305-7777
Debt
Debt-to-Equity Ratio0.67
Current Ratio15.57
Quick Ratio15.47
Price-To-Earnings
Trailing P/E Ratio-6.62
Forward P/E Ratio-5.81
P/E GrowthN/A
Sales & Book Value
Annual Sales$350,000.00
Price / Sales2,960.65
Cash FlowN/A
Price / CashN/A
Book Value$6.93 per share
Price / Book3.97
Profitability
EPS (Most Recent Fiscal Year)($4.16)
Net Income$-137,480,000.00
Net MarginsN/A
Return on Equity-72.18%
Return on Assets-39.69%
Miscellaneous
Employees251
Outstanding Shares37,640,000
Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions
What is Flexion Therapeutics' stock symbol?
Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."
How were Flexion Therapeutics' earnings last quarter?
Flexion Therapeutics (NASDAQ:FLXN) posted its earnings results on Tuesday, May, 8th. The specialty pharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.33) by $0.23. The specialty pharmaceutical company had revenue of $2.19 million for the quarter, compared to analyst estimates of $1.99 million. View Flexion Therapeutics' Earnings History.
What price target have analysts set for FLXN?
9 Wall Street analysts have issued twelve-month price objectives for Flexion Therapeutics' stock. Their predictions range from $36.00 to $570.00. On average, they anticipate Flexion Therapeutics' stock price to reach $99.00 in the next year. View Analyst Ratings for Flexion Therapeutics.
Who are some of Flexion Therapeutics' key competitors?
Some companies that are related to Flexion Therapeutics include Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT) and The Medicines (MDCO).
Who are Flexion Therapeutics' key executives?
Flexion Therapeutics' management team includes the folowing people:
- Dr. Michael D. Clayman, Co-Founder, Pres, CEO, Principal Financial & Accounting Officer and Director (Age 66)
- Dr. Neil Bodick M.D., Ph.D., Co-Founder & Chief Scientific Officer (Age 71)
- Mr. Frederick W. Driscoll, Advisor (Age 67)
- Scott Young, Sr. Director of Corp. Communications & Investor Relations
- Ms. Carolyn Beaty Scimemi Esq., Chief Compliance Officer
Has Flexion Therapeutics been receiving favorable news coverage?
Media headlines about FLXN stock have been trending somewhat positive recently, according to Accern. The research group rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Flexion Therapeutics earned a daily sentiment score of 0.13 on Accern's scale. They also gave media stories about the specialty pharmaceutical company an impact score of 46.69 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Flexion Therapeutics' major shareholders?
Flexion Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.94%), Rubric Capital Management LP (5.38%), Wells Fargo & Company MN (4.46%), Millennium Management LLC (1.84%), Wasatch Advisors Inc. (1.68%) and Schroder Investment Management Group (1.36%). Company insiders that own Flexion Therapeutics stock include C Ann Merrifield, Frederick W Driscoll, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Institutional Ownership Trends for Flexion Therapeutics.
Which institutional investors are selling Flexion Therapeutics stock?
FLXN stock was sold by a variety of institutional investors in the last quarter, including Bamco Inc. NY, BlackRock Inc., Wasatch Advisors Inc., Wells Fargo & Company MN, JPMorgan Chase & Co., Gagnon Securities LLC, Allianz Asset Management GmbH and Schroder Investment Management Group. View Insider Buying and Selling for Flexion Therapeutics.
Which institutional investors are buying Flexion Therapeutics stock?
FLXN stock was bought by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Millennium Management LLC, UBS Group AG, California Public Employees Retirement System, Trexquant Investment LP, Wexford Capital LP, Cubist Systematic Strategies LLC and DekaBank Deutsche Girozentrale. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Insider Buying and Selling for Flexion Therapeutics.
How do I buy shares of Flexion Therapeutics?
Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Flexion Therapeutics' stock price today?
One share of FLXN stock can currently be purchased for approximately $27.53.
How big of a company is Flexion Therapeutics?
Flexion Therapeutics has a market capitalization of $1.04 billion and generates $350,000.00 in revenue each year. The specialty pharmaceutical company earns $-137,480,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Flexion Therapeutics employs 251 workers across the globe.
How can I contact Flexion Therapeutics?
Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]
MarketBeat Community Rating for Flexion Therapeutics (FLXN)
MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote "Outperform" if you believe FLXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Flexion Therapeutics (NASDAQ:FLXN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for Flexion Therapeutics in the last 12 months. Their average twelve-month price target is $99.00, suggesting that the stock has a possible upside of 259.61%. The high price target for FLXN is $570.00 and the low price target for FLXN is $36.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.89 | 2.89 | 2.89 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | $99.00 | $99.00 | $99.1111 | $98.3333 |
| Price Target Upside: | 259.61% upside | 303.26% upside | 338.74% upside | 309.89% upside |
Flexion Therapeutics (NASDAQ:FLXN) Consensus Price Target History
Flexion Therapeutics (NASDAQ:FLXN) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Flexion Therapeutics (NASDAQ:FLXN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Flexion Therapeutics (NASDAQ FLXN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 14.59%
Institutional Ownership Percentage: 97.05%
Flexion Therapeutics (NASDAQ FLXN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/21/2017 | Neil Bodick | Insider | Buy | 2,700 | $24.49 | $66,123.00 | 64,605 |  |
| 11/8/2017 | Michael D Clayman | Insider | Buy | 5,000 | $23.60 | $118,000.00 | 35,395 | |
| 9/5/2017 | Yamo Deniz | Insider | Buy | 1,000 | $24.20 | $24,200.00 | 5,000 | |
| 9/1/2017 | Yamo Deniz | Insider | Buy | 3,000 | $24.15 | $72,450.00 | 5,000 | |
| 8/31/2017 | Yamo Deniz | Insider | Buy | 1,375 | $25.40 | $34,925.00 | 5,000 | |
| 6/16/2017 | Mark Stejbach | Director | Buy | 1,580 | $17.02 | $26,891.60 | | |
| 6/5/2017 | Michael D Clayman | Insider | Buy | 5,000 | $17.23 | $86,150.00 | 20,146 | |
| 4/17/2017 | Neil Bodick | Insider | Sell | 5,000 | $28.23 | $141,150.00 | 46,137 | |
| 3/23/2017 | Frederick W Driscoll | CFO | Sell | 3,000 | $23.00 | $69,000.00 | 10,777 | |
| 3/17/2017 | Neil Bodick | Insider | Sell | 5,000 | $20.41 | $102,050.00 | 50,937 | |
| 2/24/2017 | Neil Bodick | Insider | Sell | 5,000 | $19.15 | $95,750.00 | 55,937 | |
| 1/20/2017 | Neil Bodick | Insider | Sell | 5,000 | $18.35 | $91,750.00 | 60,937 | |
| 12/21/2016 | Neil Bodick | Insider | Sell | 10,000 | $18.46 | $184,600.00 | 65,937 | |
| 12/1/2016 | Samuel D Colella | Director | Buy | 10,000 | $16.38 | $163,800.00 | 25,504 | |
| 11/23/2016 | Michael D Clayman | Insider | Buy | 1,667 | $18.41 | $30,689.47 | 30,721 | |
| 11/22/2016 | Michael D Clayman | Insider | Buy | 1,666 | $17.95 | $29,904.70 | 29,054 | |
| 11/21/2016 | Michael D Clayman | Insider | Buy | 1,666 | $17.90 | $29,821.40 | 27,388 | |
| 11/21/2016 | Samuel D Colella | Director | Buy | 33,333 | $18.00 | $599,994.00 | 25,504 | |
| 6/21/2016 | Samuel D Colella | Director | Buy | 25,504 | $13.71 | $349,659.84 | 3,435 | |
| 6/20/2016 | Samuel D Colella | Director | Buy | 6,778 | $13.84 | $93,807.52 | 3,435 | |
| 6/14/2016 | C Ann Merrifield | Director | Buy | 1,000 | $13.39 | $13,390.00 | 2,000 | |
| 6/8/2016 | Samuel D Colella | Director | Buy | 714,285 | $14.00 | $9,999,990.00 | | |
| 5/20/2016 | Michael D Clayman | CEO | Buy | 2,000 | $10.41 | $20,820.00 | 13,568 | |
| 5/19/2016 | Michael D Clayman | CEO | Buy | 2,000 | $9.65 | $19,300.00 | 11,568 | |
| 5/19/2016 | Neil Bodick | Insider | Buy | 850 | $10.00 | $8,500.00 | 75,937 | |
| 5/18/2016 | Michael D Clayman | CEO | Buy | 2,000 | $10.23 | $20,460.00 | 9,568 | |
| 5/18/2016 | Neil Bodick | Insider | Buy | 2,100 | $10.20 | $21,420.00 | 75,087 | |
| 5/17/2016 | Frederick W Driscoll | CFO | Buy | 2,500 | $9.87 | $24,675.00 | 8,434 | |
| 5/17/2016 | Michael D Clayman | CEO | Buy | 2,000 | $9.73 | $19,460.00 | 7,568 | |
| 5/17/2016 | Neil Bodick | Insider | Buy | 800 | $9.60 | $7,680.00 | 72,987 | |
| 5/16/2016 | Frederick W Driscoll | CFO | Buy | 2,500 | $9.19 | $22,975.00 | 5,934 | |
| 5/16/2016 | Michael D Clayman | CEO | Buy | 2,000 | $9.51 | $19,020.00 | 5,568 | |
| 5/16/2016 | Neil Bodick | Insider | Buy | 1,250 | $9.22 | $11,525.00 | 71,937 | |
| 9/11/2015 | C Ann Merrifield | Director | Buy | 1,000 | $23.00 | $23,000.00 | 1,000 | |
| 6/22/2015 | A/S Novo | Major Shareholder | Sell | 150,000 | $20.61 | $3,091,500.00 | | |
| 3/16/2015 | Neil Bodick | Insider | Sell | 4,000 | $25.28 | $101,120.00 | | |
| 3/10/2015 | Neil Bodick | Insider | Sell | 4,000 | $24.26 | $97,040.00 | | |
| 3/4/2015 | Neil Bodick | Insider | Sell | 4,000 | $23.45 | $93,800.00 | | |
| 2/26/2015 | Neil Bodick | Insider | Sell | 4,000 | $22.44 | $89,760.00 | | |
| 12/17/2014 | A/S Novo | Major Shareholder | Buy | 500,000 | $17.00 | $8,500,000.00 | | |
| 2/18/2014 | A/S Novo | Insider | Buy | 692,308 | $13.00 | $9,000,004.00 | | |
| 2/18/2014 | Bradley J Phd Bolzon | Director | Buy | 307,692 | $13.00 | $3,999,996.00 | | |
| 2/18/2014 | Sofinnova Partners Sas | Major Shareholder | Buy | 230,769 | $13.00 | $2,999,997.00 | | |
(Data available from 1/1/2013 forward)
Flexion Therapeutics (NASDAQ FLXN) News Headlines
| Source: |
|
Flexion Therapeutics (NASDAQ:FLXN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Flexion Therapeutics (NASDAQ:FLXN) Income Statement, Balance Sheet and Cash Flow Statement
Flexion Therapeutics (NASDAQ FLXN) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
